When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Fidanacogene elaparvovec - Wikipedia

   en.wikipedia.org/wiki/Fidanacogene_elaparvovec

   In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...

3. Etranacogene dezaparvovec - Wikipedia

   en.wikipedia.org/wiki/Etranacogene_dezaparvovec

   Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. [ 5 ] [ 6 ] [ 7 ] Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX . [ 7 ]

4. FDA Approves Pfizer's Second Hemophilia Drug With Six Months

   www.aol.com/fda-approves-pfizers-second...

   Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via

5. Haemophilia B - Wikipedia

   en.wikipedia.org/wiki/Haemophilia_B

   Haemophilia B, also spelled hemophilia B, is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A). [3] Haemophilia B was first recognized as a distinct disease entity in 1952. [4]

6. Hemophilia B Treatment Market Surges with 7.6% CAGR, set to ...

   lite.aol.com/tech/story/0022/20241125/9277823.htm

   The global hemophilia B treatment market is growing rapidly, powered by gene therapy innovations, extended half-life factor IX products, and an increased concentration on personalized care. The industry players can make the most of the advanced therapeutic developments of Hemgenix, a gene therapy approved by the FDA, and recombinant factor IX ...

7. Gene therapy cures patients with hemophilia B - AOL

   www.aol.com/gene-therapy-cures-patients...

   Story at a glance Hemophilia B occurs when patients lack sufficient levels of the blood protein factor IX. Some current treatments for the condition involve repeated infusions of the protein. But ...